Structure-activity relationships of the human prothrombin kringle-2 peptide derivative NSA9: Anti-proliferative activity and cellular internalization

Biochemical Journal

Volumn 395, Issue 1, 2006, Pages 165-172

  Hwang, Hyun Sook ^a   Kim, Dong Won ^a   Kim, Soung Soo ^a  

^a Yonsei University   (South Korea)

Author keywords

Anti angiogenesis; Derivative; Endothelial cell proliferation; Flow cytometry; NSA9; Structure activity relationship (SAR)

Indexed keywords

BIOASSAY; BIOLOGICAL ORGANS; CELL CULTURE; ENZYME INHIBITION; PROTEINS; TUMORS;

ANTI-ANGIOGENESIS; ENDOTHELIAL CELL PROLIFERATION; FLOW CYTOMETRY; LEWIS LUNG CARCINOMA (LLC); NSA9; STRUCTURE-ACTIVITY RELATIONSHIP (SAR);

GENETIC ENGINEERING;

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMINO ACID; ANGIOGENESIS INHIBITOR; HUMAN PROTHROMBIN KRINGLE 2 PROTEIN; PEPTIDE DERIVATIVE; PEPTIDE NSA7; PEPTIDE NSA8; PEPTIDE NSA9; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CANCER; CAPILLARY ENDOTHELIUM; CARBOXY TERMINAL SEQUENCE; CELL LINE; CELL PROLIFERATION; COW; DRUG POTENCY; DRUG SYNTHESIS; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REACTION ANALYSIS; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; UMBILICAL VEIN;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; CATTLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; ENDOCYTOSIS; ENDOTHELIAL CELLS; HUMANS; KRINGLES; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDES; PROTHROMBIN; STRUCTURE-ACTIVITY RELATIONSHIP;

BOVINAE; MURINAE;

EID: 33645564863     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20051300     Document Type: Article

References (47)

1. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31
2. Browder, T., Folkman, J. and Pirie-Shepherd, S. (2000) The hemostatic system as a regulator of angiogenesis. J. Biol. Chem. 275, 1521-1524
3. Folkman, J. and Shing, Y. (1992) Angiogenesis. J. Biol. Chem. 267, 10931-10934
4. Cao, Y., Ji, R. W., Davidson, D., Schaller, J., Marti, D., Söhndel, S., McCance, S. G., O'Reilly, M. S., Llinás, M. and Folkman, J. (1996) Kringle domains of human angiostatin, characterization of the anti-proliferative activity on endothelial cells. J. Biol. Chem. 271, 29461-29467
5. Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A. and Bouck, N. P. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. U.S.A. 87, 6624-6628
6. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R. and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285
7. Bikfalvi, A. (2004) Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/VEGER system. Biochem. Pharmcol. 68, 1017-1021
8. Lee, T. H., Rhim, T. and Kim, S. S. (1998) Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J. Biol. Chem. 273, 28805-28812
9. Ferrara, N. (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280, C1358-C1366
10. Rehman, S. and Jayson, G. C. (2005) Molecular imaging of antiangiogenic agents. Oncologist 10, 92-103
11. Nyberg, P., Xie, L. and Kalluri, R. (2005) Endogenous inhibitors of angiogenesis. Cancer Res. 65, 3967-3979
12. Dings, R. P. M., Nesmelova, I., Griffioen, A. W. and Mayo, K. H. (2003) Discovery and development of anti-angiogenic peptides: a structural link. Angiogenesis 6, 83-91
13. Tamai, I., Sai, Y., Kobayashi, H., Kamata, M., Wakamiya, T. and Tsuji, A. (1997) Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. J. Pharmacol. Exp. Ther. 280, 410-415
14. Wender, P. A., Mitchell, D. J., Pattabiraman, K., Pelkey, E. T., Steinman, L. and Rothbard, J. B. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U.S.A. 97, 13003-13008
15. Werkmeister, J. A., Hewish, D. R., Kirkpatrick, A. and Rivett, D. E. (2002) Sequence requirements for the activity of membrane-active peptides. J. Pept. Res. 60, 232-238
16. Griffioen, A. W., Van der Schaft, D. W. J., Barendsz-Janson, A. F., Cox, A., Struijker Boudier, H. A. J., Hillen, H. F. P. and Mayo, K. H. (2001) Anginex, a designed peptide that inhibits angiogenesis. Biochem. J. 354, 233-242
17. Van der Schaft, D. W. J., Dings, R. P. M., De Lussanet, Q. G., Van Eijk, L. I., Nap, A. W., Beets-Tan, R. G. H., Bouma-Ter Steege, J. C. A., Wagstaff, J., Mayo, K. H. and Griffioen, A. W. (2002) The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J. 16, 1991-1993
18. Dings, R. P. M., Arroyo, M. M., Lockwood, N. A., Van Eijk, L. I., Haseman, J. R., Griffioen, A. W. and Mayo, K. H. (2003) β-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biocbem. J. 373, 281-288
19. Mayo, K. H., Dings, R. P. M., Flader, C., Nesmelova, I., Hargittai, B., Van der Schaft, D. W. J., Van Eijk, L. I., Walek, D., Haseman, J., Hoye, T. R. and Griffioen, A. W. (2003) Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J. Biol. Chem. 278, 45746-45752
20. Wickström, S. A., Alitalo, K. and Keski-Oja, J. (2004) An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J. Biol. Chem. 279, 20178-20185
21. Morbidelli, L., Donnini, S., Chillemi, F., Giachetti, A. and Ziehe, M. (2003) Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin. Cancer Res. 9, 5358-5369
22. Cattaneo, M. G., Pola, S., Francescato, P., Chillemi, F. and Vicentini, L. M. (2003) Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp. Cell. Res. 283, 230-236
23. Chillemi, F., Francescato, P., Ragg, E., Cattaneo, M. G., Pola, S. and Vicentini, L. (2003) Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities. J. Med. Chem. 46, 4165-4172
24. Cho, H., Kim, W. J., Lee, Y. M., Kim, Y. M., Kwon, Y. G., Park, Y. S., Choi, E. Y. and Kim, K. W. (2004) N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent. Onco. Rep. 11, 191-195
25. 2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res. 65, 3656-3663
26. Tolsma, S. S., Volpert, O. V., Good, D. J., Frazier, W. A., Polverini, P. J. and Bouck, N. (1993) Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell. Biol. 122, 497-511
27. Dawson, D. W., Volpert, O. V., Pearce, S. F. A., Schneider, A. J., Silverstein, R. L., Henkin, J. and Bouck, N. P. (1999) Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol. Pharmacol. 55, 332-338
28. Reiher, F. K., Volpert, O. V., Jimenez, B., Crawford, S. E., Dinney, C. P., Henkin, J., Haviv, F., Bouck, N. P. and Campbell, S. C. (2002) Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int. J. Cancer 98, 682-689
29. 3 integrin and inhibits angiogenesis. J. Biol. Chem. 276, 31959-31968
30. Bakre, M. M., Zhu, Y., Yin, H., Burton, D. W., Terkeltaub, R., Deftos, L. J. and Varner, J. A. (2002) Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nat. Med. 8, 995-1003
31. Tan, D. C. W., Kini, R. M., Jois, S. D. S., Lim, D. K. F., Xin, L. and Ge, R. (2001) A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor. FEBS Lett. 494, 150-156
32. Kim, T. H., Kim, E., Yoon, D., Kim, J., Rhim, T. Y. and Kim, S. S. (2002) Recombinant human prothrombin kringles have potent anti-angiogenic activities and inhibit Lewis lung carcinoma tumor growth and metastases. Angiogenesis 5, 191-201
33. Kim, B. J., Koo, S. Y. and Kim, S. S. (2002) A peptide derived from human prothrombin fragment 2 inhibits prothrombinase and angiogenesis. Thromb. Res. 106, 81-87
34. Chang, C. D. and Meienhofer, J. (1978) Solid-phase peptide synthesis using mild base cleavage of N α-fluorenylmethyloxycarbonylamino acids, exemplified by a synthesis of dihydrosomatostatin. Int. J. Pept. Protein Res. 11, 246-249
35. Vistica, D. T., Skehan, P., Scudiero, D., Monks, A., Pittman, A. and Boyd, M. R. (1991) Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res. 51, 2515-2520
36. Montesano, R., Vassalli, J. D., Baird, A., Guillemin, R. and Orci, L. (1986) Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. U.S.A. 83, 7297-7301
37. John, H., Radtke, K., Ständker, L. and Forssmann, W. G. (2005) Identification and characterization of novel endogenous proteolytic forms of the human angiogenesis inhibitors restin and endostatin. Biochim. Biopnys. Acta 1747, 161-170
38. Hwang, H. S. and Kim, S. S. (2005) The human prothrombin kringle-2 derived peptide, NSA9, is internalized into bovine capillary endothelial cells through endocytosis and energy-dependent pathways. Biochem. Biophys. Res. Commun. 335, 469-476
39. Kieber-Emmons, T., Murali, R. and Greene, M. I. (1997) Therapeutic peptides and peptidomimetics. Curr. Opin. Biotechnol. 8, 435-441
40. Chen, Y., Muhlrad, A., Shteyer, A., Vidson, M., Bab, I. and Chorev, M. (2002) Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP (10-14). J. Med. Chem. 45, 1624-1632
41. Nomizu, M., Weeks, B. S., Weston, C. A., Kim, W. H., Kleinman, H. K. and Yamada, Y. (1995) Structure-activity study of a laminin α1 chain active peptide segment Ile-Lys-Val-Ala-Val (IKVAN). FEBS Lett. 365, 227-231
42. Ido, Y., Vindigni, A., Chang, K., Stramm, L., Chance, R., Heath, W. F., DiMarchi, R. D., Di Cera, E. and Williamson, J. R. (1997) Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science (Washington DC) 277, 563-566
43. Doi, M., Ishibe, A., Shinozaki, H., Murata, T., Inoue, M., Yasuda, M. and Ishida, T. (1995) Conserved δ-activity in reverse enantiomeric opioid peptide. Life Sci. 19, 1557-1562
44. Bab, I. and Chorev, M. (2002) Osteogenic growth peptide: from concept to drug design. Biopolymer 66, 33-48
45. Juvvadi, P., Vunnaam, S., Yoo, B. and Merrifield, R. B. (1999) Structure-activity studies of normal and retro pig cecropin-melittin hybrids. J. Peptide Res. 53, 244-251
46. Bessalle, R., Kapitkovsky, A., Gorea, A., Shalit, I. and Fridkin, M. (1990) AII-D-magainin: chirality, antimicrobial activity and proteolytic resistance. FEBS Lett. 274, 151-155
47. Apletalina, E. V., Juliano, M. A., Juliano, L. and Lindberg, I. (2000) Structure-function analysis of the 7B2 CT peptide. Biochem. Biophys. Res. Commun. 267, 940-942